Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Sun

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Nature Communications|October 4, 2024
Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic riskBryan R Gorman, Sun-Gou Ji, Michael Francis, et al.
Journal of the National Cancer Institute|February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trialsEric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Nature Communications|February 24, 2023
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitisYounghun Han, Jinyoung Byun, Catherine Zhu, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy SpecimensMingxuan Xu, Coya Tapia, Joud Hajjar, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Nature Communications|October 4, 2024
Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic riskBryan R Gorman, Sun-Gou Ji, Michael Francis, et al.
Journal of the National Cancer Institute|February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trialsEric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Nature Communications|February 24, 2023
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitisYounghun Han, Jinyoung Byun, Catherine Zhu, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy SpecimensMingxuan Xu, Coya Tapia, Joud Hajjar, et al.
Pageof 11